A nationwide survey of
late effects in survivors of juvenile myelomonocytic leukemia in Japan
Shuichi Ozono1,11*, Kazuo
Sakashita2,11, Nao Yoshida3,11,
Harumi Kakuda4,11, Kenichiro
Watanabe5,11, Miho Maeda6,11,
Yasushi Ishida7,11, Atsushi
Manabe8,11, Takashi Taga9,11, Hideki
Muramatsu10,11
1: Kurume University School of Medicine, Department of
Pediatrics and Child Health
2: Department of Hemato-Oncology, Nagano prefectural
children’s hospital
3: Department of Hematology and Oncology, Children’s
Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
4: Department of Hemato-Oncology, Chiba prefectural
children’s hospital
5: Department of Hemato-Oncology, Shizuoka prefectural
children’s hospital
6: Department of Pediatrics, Nippon Medical School
7: Department of Pediatrics, Ehime prefectural central
hospital
8: Department of Pediatrics, Graduate School of
Medicine, Hokkaido University
9: Department of Pediatrics, Shiga Medical College,
School of Medicine
10: Department of Pediatrics, Nagoya University
Graduate School of Medicine
11: Japan Children’s Cancer Group (JCCG)
*Correspondence to:
Shuichi Ozono, MD, PhD, Department of Pediatrics, Kurume University
School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
Tel.: +81-942-31-7565, Fax: +81-942-38-1792, E-mail:
ohzono_shyuuichi@kurume-u.ac.jp